Related Experiment Video
Updated: Aug 9, 2026
07:52
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Factors for increased morbidity and mortality in uremia: hyperphosphatemia
Nathan W Levin1, Frank A Gotch, Martin K Kuhlmann
1Renal Research Institute, New York, NY 10128, USA. nlevin@rriny.com
Seminars in Nephrology
|October 19, 2004
Summary
Hyperphosphatemia, high inorganic phosphorus (iP) in dialysis patients, is a significant uremic toxin. Current treatments often fail to normalize iP levels, necessitating new evaluation models for dialysis prescriptions.
Area of Science:
- Nephrology
- Urology
- Metabolic Disorders
Background:
- Hyperphosphatemia is a common metabolic abnormality in patients undergoing dialysis.
- Inorganic phosphorus (iP) is recognized as a uremic toxin due to its adverse effects.
- Achieving normal phosphorus levels in dialysis patients remains a therapeutic challenge.
Purpose of the Study:
- To evaluate the significance of hyperphosphatemia in hemodialysis patients.
- To review current therapeutic strategies for managing hyperphosphatemia.
- To introduce a novel model for assessing the inorganic phosphorus balance in dialysis prescriptions.
Main Methods:
- Literature review of hyperphosphatemia in dialysis.
- Analysis of current therapeutic approaches.
- Description of a new model for evaluating iP balance in dialysis prescriptions.
Main Results:
- Hyperphosphatemia significantly impacts dialysis patients.
- Existing therapies frequently fall short of normalizing iP levels.
- A new model is proposed for better management of iP balance.
Conclusions:
- Effective management of hyperphosphatemia in dialysis patients is crucial.
- Current therapeutic options are often insufficient.
- The proposed model offers a new perspective for optimizing dialysis prescriptions to control iP levels.
Related Concept Videos
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:25Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
01:25Peritoneal Dialysis III: Nursing Management
Peritoneal dialysis, or PD, utilizes the peritoneal membrane as a filter to eliminate excess fluid and waste products. Effective nursing management is essential for ensuring patient safety, preventing complications, and promoting optimal function of the peritoneal dialysis process.Assessment and MonitoringNurses must thoroughly assess the patient before, during, and after each dialysis session. Regular monitoring includes vital signs, daily weight, fluid intake and output, and laboratory values...
01:24Hemodialysis II: Procedure and Complications
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:28Chronic Kidney Disease III: Interprofessional Care
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...